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A major use of gold compounds in the pharmaceutical industry is for anti -
arthritic agents. The disease itself is not understood and little is known about
the way in which the drugs act, but detailed pictures of the distribution of gold
in the body are available, and some of the relevant biochemistry is beginning to
emerge.
Gold is normally present in human and animal tissues in
only minute proportions. The the element has no known
natural biological function, although some algae are able to
absorb considerable quantities of gold from solution and
there is one plant species known to concentrate the metal.
Many gold compounds are highly toxic to animals, espe-
cially chloroauric acid and its salts, largely because of their
oxidising ability. Nevertheless, gold and its compounds have
a long history of medical application (1). In this century, a
few gold compounds have been used very successfully in
the treatment of rheumatoid arthritis (2). In the last year, a
new compound has been approved for general use in this
field (3), and another new material shows promise as an
anti-tumour agent (4). As might be expected for drugs
containing a heavy metallic element which has no natural
function, there are some side effects, notably skin rashes,
diarrhoea and nephrosis, and some patients cannot tolerate
this form of treatment (5, 6). Those who can, however, may
well experience actual remission of the disease.
Very little is known about the way in which the gold-
containing drugs act. This is partly because the origin of
rheumatoid arthritis is itself not understood, but also be-
cause the biological chemistry of gold has been little stud-
ied. Indeed, despite intensive work over the Iast few years,
even the precise details of the molecular structures of the
established drugs themselves remain obscure; if attempts
were being made to introduce them today as new drugs, it
is unlikely that their use would be sanctioned.
The purpose of this article is to give a survey of the
types of compounds presently employed in medicine, of the
distribution of gold in the body which results from their
use, and of some relevant chemistry. Emphasis is placed on
results obtained in the last few years; other reviews give
good coverage of earlier work (7, 8).
The Drugs
The effective compounds are all gold(I) thiolates, that is,
they involve AuSR units, where R is a suitable organic
group. There are several practical reasons for this choice.
First, the gold should be univalent, to avoid the toxicity as-
sociated with the oxidising power of the more normal
trivalent state. Second, in order to stabilise the gold(I)
against disproportionation into inactive elemental gold and
toxic gold(III), the gold must be bound to groups (ligands)
with which it can form strong covalent bonds. These ligands
must therefore be `soft', i.e. bound to gold through atoms
of relatively low electronegativity, such as sulphur, phos-
phorus or carbon - the `harder' oxygen, nitrogen and Nalo-
gens will not do. These soft ligands also give the com-
pounds good stability 'on the she1P. Third, the ligands must
not be so tightly bound, nor the compounds so stable, that
metabolic reactions will not occur. Such reactions are likely
to be the means by which the gold is transported within the
body, and are certainly the cause of the therapeutic activity.
Thiolates meet these criteria well. In the traditional an-
tiarthritics they are the sole ligands, so the drugs have the
general formula AuSR. The two most commonly used
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compounds are those in which the organic group is a sugar







solution. The solid compounds are usually obtained as
amorphous powders, and crystals suitable for X-ray exami-
nation have never been obtained. The precise molecular
structures have therefore not yet been established. Data
from a variety of other techniques indicate polymeric
structures in which the sulphur atoms form bridges be-
tween adjacent gold atoms (9-14). Each gold atom is










The use of these groups means that the compounds are
soluble in water, and they are administered by injection of a
This form of linear coordination is very common fo
gold(I). Structures involving these units could be close(
rings or open chains; both forms are known for analogou!
silver(I) thiolates, depending on the size and shape of the F
group and, sometimes, on whether the solid or its solutioi
is examined (15-17). Very recently, data from wide-angl+
scattering and absorption-edge fine structure mea
surements with X-rays (WAXS and EXAFS) have beef
interpreted in favour of the linear structure both for solii
Myocrisin and for its aqueous solutions (18). Such a struc
ture requires the presence of an `extra' thiolate ligand t,
cap the `bare' gold atom at the end of each chain, and it ha
been noted that conventional preparations of Myocrisi
contain a slight excess of thiomalate (19).
The newly introduced compound Auranofin (c
Ridaura) involves an acetylated thioglucose group. Hom
ever, this compound is monomeric by virtue of the presenc
of a phosphine ligand, so that the coordination of the go!
is P-Au-S.
This compound can be readily crystallised, and its structur
in the solid state is accurately known (20). Both it and ii
immediate metabolite (the de-acetylated form) (21) ar
only sparingly soluble in water, but they have good lipi
solubility, and can be absorbed through the intestin
Auranofin is therefore administered orally as the solid.]
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this form, only 20-25 per cent of each dose is absorbed into
the body, the remainder being eliminated faecally (22). Re-
cent animal studies show that administration of a solution
in 5 per cent aqueous alcohol leads to effectively complete
uptake of the drug (23).
Some workers believe that it is the thiolate part of the
drug which is the active entity, and that the gold com-
pounds serve only as a means of introducing them into the
body. Analogies have been drawn between the molecular
structure of Myocrisin and penicillamine, which has also
been used to treat arthritis (24-26). Sodium thiomalate it-
self does have slight efficacity against rheumatoid arthritis,
but has to be given in considerably larger doses than Myo-
crisin (27). A wide variety of gold compounds has now been
shown to be active, including some which possess no thio-
late ligands at all, so the metal can be identified as the
common therapeutic factor. As indicated above, it is the
role of the ligands to stabilise and carry the gold.
Distribution and Metabolism
The two types of drugs are administered differently. Aura-
nofin has the advantage that it can be taken like conven-
tional medicines, by mouth; doses of 2.5 mg per day are
normal. Unfortunately, if Myocsrisin or Solganol are given
Gold Bull., 1987, 20, (1/2)
in this way, they are promptly and drastically eliminated.
Administration is therefore by injection of an aqueous so-
lution, usually in the gluteal muscle, at weekly doses of 25-
50 mg. Since the treatment is long-term, the patients re-
ceive comparable amounts of gold whichever type of drug
is used. However, because solid Auranofin is rather ineffi-
ciently absorbed, the actual effective dose is considerably
less.
After administration, the drug will begin to be absorbed
and metabolised. It is important to realise that the species
which exerts the actual therapeutic effect may, in a chemi-
cal sense, be very different from the drug itself. This is true
of all drugs, but especially those containing metallic ele-
ments. To understand how the drugs work (and the origin
of unwanted side effects) it is necessary to study their
metabolism. However, before this can be attempted,
knowledge is needed of the way in which the administered
gold moves around the body. That is, the concentration of
gold in various organs, tissues, and body fluids must be
measured over periods of several days or, preferably,
weeks.
Two major methods are available. The first is direct
analysis of samples by methods such as neutron activation
or atomic absorption. These techniques can be readily ap-
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Fig. 1	 Distribution of gold in various organs of rats after
administration of Myocrisin or Auranofin at 2.5 mg/kg. Note that the
horizontal scale is logarithniic
plied to blood or excrement, for which samples can be ob-
tained easily without harm to the patient. Other organs are
generally available only post mortem or after surgery. A
better method, in principle at least, is to use radioactive
isotopes of gold. Approximate distribution patterns can be
obtained by monitoring the radiation externally to the body,
but accurate results can again be obtained only by taking
surgical samples of the organs, etc. In consequence, the
most detailed studies have been made with animals: rats,
mice, guinea pigs, and dogs have all been used. Fortunately,
these data seem broadly to parallel those for humans (28).
The results of a recent detailed comparison of Myo-
crisin and Auranofin in rats (23) are shown in Figure 1.
The data were obtained by preparing samples of the drugs
containing radioactive gold-199, which were administered
at doses comparable with those normally given to human
patients. It is evident that, after about 24 hours, there are
no major differences in the distribution of gold from the
two drugs, despite the differences in their molecular struc-
ture and in the mode of administration.* However, it is also
* It should be noted that, in this trial, Auranofin was given by
mouth but was in solution. This led to effectively complete
uptake of the drug, rather than the ca. 20% which is normal
when the solid drug is adrninistered. In other studies, there-
fore, the amounts of gold recorded are 4-5 times less for
Auranofin than shown here.
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obvious that Myocrisin is absorbed almost instantly into the
blood stream, by which it is rapidly transported throughout
the body. Clearance of gold from the blood by kidney, liver
and spleen begins immediately, and the blood level drops
accordingly. In contrast, gold from Auranofin is adsorbed
only slowly. Clearly, some metabolic reactions have to oc-
cur before the drug can pass through the stomach or in-
testinal wall, and it has been shown that this is almost cer-
tainly the removal of the acetyl groups from the thioglucose
unit (21). Once in the blood, the gold is removed by the
kidney, liver and spleen, just as for Myocrisin. The levels
attained in these organs are about two times lower than
those from Myocrisin (and lower still when solid Auranofin
is used), giving hope of lessened toxicity. Both drugs give
small but significant gold levels in the skin, which is con-
sistent with the appearance of rashes as a common side ef-
fect. There is, however, no direct correlation between gold
levels and the occurrence of rashes; patients differ in
sensitivity.
Perhaps the most interesting observation is that the
joints accumulate appreciably more gold (about twice as
much) than the surrounding bone. Since the synovium of
the joint is the affected tissue in rheumatoid arthritis, it is
significant that the therapeutic metal manages to reach this
area. There are indications that affected joints take up
more gold than normal joints (29).
When the masses of the various organs are taken into
account, about 50 per cent of the administered gold is pre-
sent in the blood, kidney, liver and skin after 24 hours.
There is then a slow decline, with Auranofin-gold being lost
slightly more rapidly. After six months, considerably more
Myocrisin-gold is retained in the body (30), and gold can be
detected many years after administration has been stopped.
When administration is continuous, blood levels sta-
bilise at 30-50 pg per ml (31, 32). The actual concentrations
vary from individual to individual, and there appears to be
no correlation between the therapeutic effect and blood
level. Most of the gold from Myocrisin is present in the
serum, very little passes into the red cells. There is some
evidence that smoking increases the cell-content, the
transfer being assisted by the raised levels of cyanide in the
blood (33, 34). It has also been suggested that the cell-
content may be an indicator of the likelihood of toxic reac-
tions (35). In the serum, the majority (80-90 per cent) of
the gold is associated with albumin, and most of the re-
mainder with globulins. The former is lost more rapidly
that the latter, so that the balance changes over 3-4 weeks
following a single injection (36). For Auranofin, gold in the
blood is distributed more evenly between serum and cells,
but the latter is cleared slightly more rapidly, so that the
equilibrium distribution is not unlike that from Myocrisin
(37, 38). The ability of Auranofin-gold to pass through the
cell wall is probably due to the fact that it, and its primary
metabolite, are relatively non-polar molecules.
With both drugs, a small proportion of gold is present
in the blood as species with low molecular weight, and this
has been described as `free', 'reactive', or 'unbound' gold
(39). However, this form clears rapidly, probably by urinary
excretion, and is unlikely to have any therapeutic role.
Of the organs responsible for the clearance of gold
from the bloodstream, the kidney develops the highest con-
centrations (40). The presence of gold in this organ may be
responsible for some of the toxic reactions, e.g. proteinurea
(loss of protein in the urine) or haematuria (loss of blood
into the urine). It has recently been found that gold in urine
(rat) is associated with albumin and with another protein of
high molecular weight (ca. 150 000 daltons) (41). Myo-
crisin-gold is taken up preferentially (ca. 70 per cent) by the
cortex and the lysosomes. The latter can take up large
quantities of gold, and can then be seen as dense particles
under the electron microscope (42, 43). The gold levels are
often so high that these cells have been called `aurosomes'.
Within the aurosomes, the gold is associated with sulphur
(43-45); it is presumably tightly bound and removed from
circulation, but may act as a long-term reservoir. Gel per-
meation chromatography shows four major species with
molecular weights ranging from a few hundred to about
100 000 daltons (10). The smallest is possibly a simple
complex with cysteine or glutathione, and one of the others
is probably a metallothionein complex.
In the liver, gold seems to be taken up initially by the
cytosol, forming similar species to those seen in the kidney
cortex (10), but passes rapidly to the lysosomes (46). There
is some evidence that the orally administered compounds
give somewhat lower gold levels in the liver than the in-
jected drugs, but it is not clear how far this is due to the
lower level of absorption of the former.
The patterns of elimination follow those of the uptake
by liver and kidney. A large proportion of orally adminis-
tered Auranofin is eliminated rapidly via the faeces. Some
metabolism must occur, however, because radiolabelling
experiments show that the sulphur and phosphorus from
the drug are readily absorbed, and appear principally in the
urine (22). Gold from the injected drugs is passed mainly
(ca. 70 per cent) through the kidneys to the urine.
Some Chemistry
From a chemical point of view, the body is extremely com-
plicated. Even a single fluid, such as blood serum, contains
a wide variety of molecules. Many of these are capable, in
principle at least, of binding to gold. The chemist is there-
fore tempted to simplify, to perform reactions in vitro,
where only a few chemicals are present at any one time,
and some control is possible. However, this poses a differ-
ent problem. The drugs, once administered, begin to
metabolise, to change chemically. Thus, although one may
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take a single biological component such as albumin, it is by
no means clear in what form the gold should be. For in-
stance, Auranofin appears to be absorbed as its de-acety-
lated form; model reactions using the drug itself may no
longer be relevant. Many of the earlier in vitro results
should therefore be treated with caution.
It is useful first to consider the type of chemistry which
might be involved. For the most part, the body is a reducing
environment, so the gold is unlikely to be oxidised to the
trivalent state. At the same time, there is a sufficient supply
of `soft' ligands to ensure that the gold(I) is stabilised
against reduction to the metal. The most likely reactions
are therefore those in which one or more ligands are re-
placed by others.
Gold(I) is predominantly two-coordinate, as in the
drugs themselves. A few compounds involving higher co-
ordination numbers are known, but nearly all involve
phosphine ligands e.g. Au(PPh 3)2C1 (47) and
[Au(PPh2Me)4]PF (48). Only a few compounds with sul-
phur ligands are known with three- and four-coordinate
gold, and these all have at least one phosphine ligand
bound to the gold, e.g. Au(PPh 3)2SCN (49),
Au(PPh3)3SCN (50, 51), (R3PAu)2MS4
 (M = Mo, W) (52).
As seen earlier, the phosphine ligands in the drugs are
eliminated quite rapidly, and it is unlikely that phosphine
complexes play any large role in the long-term therapeutic
effect. It is equally unlikely that any significant biological
species will show coordination numbers greater than two
for the gold. However, the ability of gold(I) to expand its
coordination shell is important in reactions in which one
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Since the incoming ligand, Z, has ready access to the gold
atom, and can be bound easily, such reactions are very
rapid and will probably be the major means by which the
gold atom `changes partners' in the biological system.
A wide variety of potential ligands is available in vivo,
with oxygen, nitrogen, and sulphur atoms as possible bind-
ing sites for the gold atom. Since gold(I) has a strong pref-
erence for `soft' ligands, it is generally assumed that any
major, long-lived species will involve sulphur-containing
groups of the thiolate type; thioethers bind much more
weakly to gold, and are readily replaced. Most studies have
therefore concentrated on the reactions of the drugs with
naturally occurring thiols such as cysteine and glutathione.
Myocrisin and other gold(I) thiolates undergo facile lig-
and-exchange reactions with a variety of thiols, including
thiomalate and cysteine (10, 53). The products obtained
depend on the composition of the mixture, but in the pres-
ence of an excess of the thiol the principal product is al-
most certainly the monomeric species Au(SR)2 . There is
spectroscopic and EXAFS evidence for such species in
which the SR group comes from thiomalate, cysteine, or
penicillamine, and the benzenethiolate derivative has re-
cently been characterised by X-ray crystallography (45, 54-
56). A range of mixed-ligand polymeric species is formed
when the amounts of the gold(I) thiolate and the added
thiol are about equal. Auranofin also undergoes facile thiol
exchange, e.g. with cysteine derivatives (57).
RS—Au?--SR HSR RS AuC—SR'
Et P—Au—S R H SR ►
 Et 3
 P—Au—S R'
In the blood stream, much gold is bound to albumin,
Serum albumin, and the bovine analogue which is often
used in model experiments, is a very large protein (molec.
ular weight about 65 000). It contains 35 cysteine residues
but most of these are paired together as the oxidised cys•
tine form, i.e. the SH-groups have joined together to forn
S-S bonds (Figure 2). Only one SH-unit is present (Cys34)
and this appears to be situated in a cleft of the globula
structure about 950 pm from the surface (58). Some ver:
elegant studies using spectroscopic, chromatographic ani
radiolabelling methods have shown that gold from Myo
crisin binds to this site (59). When the albumin is in exces;
as in the blood, a 1:1 complex is formed analogous to th
Au(SR)2 species mentioned above:
S—H + AuSTm —• S—A^ STn
—HSTm
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Fig. 2 Schematic representation of the albumin sequence, showing the
seventeen cystine S-S linkages and the unique cysteine unit
Auranofin also reacts with albumin, at the same site,
with displacement of the thioglucose (61):
S — H + Et3 P—Au—Satg —► S Au— PEt3
—HSatg	
—
This is consistent with the much more rapid elimination of
the thioglucose than the gold from the blood-stream, as
shown by experiments with the radio-sulphur labelled drug
(in rats) (56). In vitro experiments with blood (from rats or
dogs) also shown very different binding patterns for gold
and sulphur (22). It is known that the phosphine is elimi-
nated more rapidly than the gold, and in vitro experiments
confirm the separation of the phosphine from the gold (22).
It is therefore likely that secondary reactions occur, in




There is little Myocrisin-derived gold in the red blood
cells except in patients who smoke (34, 35). This effect is
attributed to raised levels of cyanide in the serum which
somehow assists the gold to pass through the cell wall. In
model experiments with Myocrisin and Au(SR)2 (e.g. HSR
= glutathione), it has been shown (62, 63) that a gold-sul-
phur bond can be broken by cyanide to give mixed-ligand
species RSAuCN-. These species undergo facile thiolate
exchange:
This complex is very stable and results in tight binding of
the gold. In vivo studies show that the thiomalate ligand is
lost from the blood much more rapidly than the gold (60),
presumably from thiolate-exchange reactions with cysteine,
glutathione, or other naturally occurring thiols. RS — A? SR SR— RS — Au^— CN
Presumably, relatively small molecules like GIuSAuCN
are able to transport gold more easily across the cell mem-
HSR	 O	 brane. NMR evidence suggests that, in the blood cells, gold
(!S:—::ASuS Tm	
— HSTm	 S — Au — S R from Myocrisin or Auranofin binds to glutathione, but the
species formed has not been identified (64).
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In kidney and liver cells, gold is found in the cytoplasm,
and there is evidence (10) for the presence of a cysteine
complex of the type Au(SR)2 . Several other gold-contain-
ing components are present, of which one bas been identi-
fied as metallothionein. Metallothionein is a protein con-
taining 61 amino-acid residues, of which 20 are cysteine.
This abundance of thiol groups gives it a powerful capacity
to bind the `softer' metals, and natural metallothionein
usually contains zinc, cadmium, and some copper. In the
fully metallated state, one molecule of metallothionein
contains seven metal atoms. In test-tube reactions with
Myocrisin, provided the Myocrisin is not in excess, up to
ten gold atoms can replace the divalent metal, with zinc be-
ing replaced in preference to cadmium (65). At the same
time, all the thiomalate is liberated. EXAFS studies show
that, as usual, the gold is linearly coordinated to two sul-
phur atoms (see below).
Curiously, Auranofm does not react with metaIlothione
in in vitro (66), although cultured epithelial cells will take
Auranofin-gold into their metallothionein (67). This un-
derlines the need to use the drug metabolites in model ex-
periments, rather than the drugs themselves. Presumably
the acetylthioglucose cannot be displaced by the cysteine
residue of the metallothionein, either for thermodynamic
or steric reasons. It is not known whether the deacetylated
form of the drug will react directly with metallothionein.
However, this is probably not relevant either since, by the
time the gold reaches the kidney, it is bound to albumin,
and may even have lost the phosphine ligand.
Anti-tumour Agents
Some gold complexes have been shown to be toxic to vari-
ous tumour cells in culture, e.g. Auranofin and Au(CN) -,
but these are not active in vivo (68, 69). By analogy with the
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clinically successful platinum-based drugs, such as cis-
PtC12 (NH3)2
 (cisplatin) and Pt[(02C) C4H6J(NH3)2
 (para-
platin), it might be thought that golcf(III) would be more
suitable than gold(I). Gold (III) is isoelectronic with plat-
inum(II), and forms similar square-planar complexes.
However, many gold(III) complexes are readily reduced to
gold(I) or gold metal, which would probably mean that they
would never reach the desired site and would instead be
toxic. It will be necessary to choose the ligands very care-
fully to prevent this. The organometallic complexes
Au(CH3)^C12 and (H 3C)2Au(SCN)2Au(CH3)2
 are effec-
tive in anti-tumour tests (70).
Very recently a new type of complex has been found to
show great promise (4). This is a four-coordinate gold(I)
complex [Au(dppe)21C1 (dppe = Ph PCH2CH2PPh2). The
more conventional compound CIAu^dppe)AuCl is also ac-
tive, but it has been shown that in blood it readily un-
dergoes disproportionation to form Au(dppe) 2 + . The
corresponding silver(I) and copper(I) complexes are also
active, as is the ligand itself. The metal complexes seem to
be rather more effective than the pure ligand, and it is
likely that the metal serves as a protective carrier for the
ligand, ensuring that it arrives intact at the active site. This
is a neat reversal of the situation for the anti-arthritic
drugs.
Conclusion
Drugs containing gold are effective agents against
rheumatoid arthritis, but their mode of action is still un-
clear. The pattern of distribution of gold in the body pro-
duced by their use is reasonably well established, and is
significantly different from those of the other components
of the drugs. Gold is retained considerably longer than
these components, and it seems certain that the therapeutic
activity is due to the gold.
Some progress has been made in understanding the
biochemistry of gold, and complexes with albumin and
metallothionein have been characterised. These studies are
at an early stage, but have emphasised the need to use the
metabolites of the drugs, rather than the drugs themselves.
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